Lung Cancer Staging Medical Slides
Generate publication-quality lung cancer staging lecture slides in 30 seconds. AI-powered content structured for clinical education.
Generate Lung Cancer Staging DeckWhy teach Lung Cancer Staging?
Lung cancer remains the leading cause of cancer death worldwide with 1.8 million deaths annually. The 8th edition TNM staging system (2017) introduced new T-category size cutoffs and reclassified several nodal and metastatic scenarios. Teaching lung cancer staging requires integration of imaging interpretation, tissue sampling techniques, molecular profiling, and PD-L1 assessment to guide therapy selection.
What AI generates for Lung Cancer Staging
Enter “Lung Cancer Staging” and SlideCraft generates a complete lecture deck with slides like these.
See it in action
Type any medical topic and watch AI generate a presentation slide in seconds. No signup required.
3 free previews per hour · No account needed
Enter a topic and click Generate to see your AI slide
Lung Cancer Staging Presentation FAQ
How should the 8th edition TNM changes be highlighted in staging slides?
Present the new T-category size cutoffs: T1a (≤1 cm), T1b (>1-2 cm), T1c (>2-3 cm), T2a (>3-4 cm), T2b (>4-5 cm), T3 (>5-7 cm), T4 (>7 cm). Emphasize the key changes from the 7th edition — size became the dominant T-descriptor, diaphragm invasion was reclassified to T4, and mediastinal pleural invasion was removed. Include the new M1a/M1b/M1c subcategories based on metastatic burden.
What molecular testing panel should be presented for NSCLC?
Present the NCCN-recommended panel: EGFR mutations (exon 19 del, L858R — erlotinib/osimertinib), ALK rearrangements (alectinib first-line per ALEX trial), ROS1 fusions (crizotinib/entrectinib), BRAF V600E (dabrafenib-trametinib), KRAS G12C (sotorasib/adagrasib), MET exon 14 skipping, RET fusions, NTRK fusions, and HER2 mutations. Emphasize reflexive broad panel NGS testing for all non-squamous NSCLC and never-smoker squamous histology.
How should PD-L1 and immunotherapy selection be covered?
Present PD-L1 TPS (tumor proportion score) cutoffs: ≥50% (pembrolizumab monotherapy per KEYNOTE-024), 1-49% (combination chemo-immunotherapy per KEYNOTE-189/407), <1% (chemo-immunotherapy, consider nivolumab-ipilimumab per CheckMate 227). Emphasize testing with 22C3 pharmDx assay, timing before first-line therapy, and that PD-L1 is an imperfect biomarker — TMB may add predictive value.
Simple pricing, no surprises
Start free today. Upgrade when your department needs more.
Free
Try SlideCraft with no commitment
- 2 decks per month
- AI slides with speaker notes
- View & present only (no export)
- 7-day cloud storage
- Slide Checker & Outline Generator
Pro
For clinicians who lecture weekly
- 10 decks/mo + $2.50/extra
- AI Critic Mode (5-axis review)
- Document-to-deck (PDF upload)
- PDF, PPTX, SCORM & image export
- Permanent cloud storage
Expert
For academic physicians who publish and present
- 25 decks/mo + $2.00/extra
- PubMed source verification
- Paper-to-deck pipeline
- Auto-citations (Vancouver)
- Everything in Pro